Clinical trials, based on anti-Tau-antibodies and -vaccines, modulators of Tau aggregation, and antisense oligonucleotides targeting its gene the microtubule associated protein tau (MAPT), are currently ongoing for AD patients (Yanamandra et al., 2015; Jadhav et al., 2019) (Table 1). This evidence concerns the gene MAPT and Alzheimer disease.